Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04243499 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of ICT01 in Patients With Advanced Cancer
A Phase 1 study of Solid Tumor, Adult and Hematopoietic/Lymphoid Cancer, sponsored by ImCheck Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 292
- Enrollment target
- 20
- Study locations
NCT04243499 is a Phase 1 study of Solid Tumor, Adult and Hematopoietic/Lymphoid Cancer that is active but no longer recruiting, run by ImCheck Therapeutics. The registered enrollment target is 292 participants, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT04243499, a Phase 1 study of Solid Tumor, Adult and Hematopoietic/Lymphoid Cancer, is active but no longer recruiting, sponsored by ImCheck Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 292 participants
- Enrollment target
- 20
- Study locations
Study Summary
Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 3 solid tumor indications for the combination of ICT01 plus pembrolizumab.
Conditions Studied
Interventions
- BIOLOGICAL IV ICT01
Study Locations (20)
Other
- Institut Jules Bordet - Brussels
- Institut Bergonie - Bordeaux
- Haut Leveque - Bordeaux
- Centre Hospitalier Lyon Sud - Lyon
- Centre Lyon Berard - Lyon
- CHU Lyon - Lyon
- Institut Paoli-Calmettes - Marseille
- CHU Nantes - Nantes
- Centre Antoine Lacassagne - Nice
- Pitie-Salpetriere - Paris
- Institut Curie - Paris
- Gustave Roussy - Paris
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- US Oncology Research - Irving
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- City of Hope Comprehensive Cancer Center - Duarte
Connecticut
- Yale Cancer Center - New Haven
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
New York
- Montefiore Medical Center - The Bronx
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2020-03-05 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04243499
The ClinicalTrials.gov registry entry for NCT04243499 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (57% higher). The listed sponsor is ImCheck Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which IV ICT01 is the first listed.
NCT04243499 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT04243499 about?
NCT04243499 is a clinical study titled "First-in-Human Study of ICT01 in Patients With Advanced Cancer". Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor...
What is the current status of trial NCT04243499?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 292 participants. The study started on 2020-03-05. Estimated completion is 2026-10.
What conditions does trial NCT04243499 study?
This clinical trial studies the following conditions: Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer.
What interventions are being tested in trial NCT04243499?
The interventions under investigation include: IV ICT01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04243499?
This trial is sponsored by ImCheck Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04243499 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.